Sharekhan

Wanbury Ltd

Tue 29/04/2025,15:45:28 NSE: WANBURY

₹ 244.42 -7.52 (-2.98%)
BUY NOW Buy Wanbury Ltd Stock

Open Free Demat and Trading account in 15 minutes

Home Stock Wanbury Ltd

Tue 29/04/2025,16:1:0

Wanbury Ltd

Tue 29/04/2025,15:45:28 | NSE : WANBURY

₹ 244.42-7.52 (-2.98%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 255.84

Previous Close

₹ 251.94

Volume

86671

Mkt Cap ( Rs. Cr)

₹800.98

High

₹ 258.25

Low

₹ 240.30

52 Week High

₹ 323.53

52 Week Low

₹ 131.20

Book Value Per Share

₹ 11.83

Dividend Yield

0.00

Face Value

₹ 10.00

What’s Your Call?

Collective community sentiment on Wanbury Ltd

Your Vote -

Buy

50.00%

Hold

16.67%

Sell

33.33%

50.00%

6 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

NaN%

Sell Order Quantity

NaN%

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Option Chain

Analyzes market sentiment, predicts Wanbury Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Wanbury - Press Release

    23 Apr 2025, 10:25AM Wanbury Limited has informed the Exchange regarding a press release dated April 23, 2025, titled ""Intimation to implement the SAP S/4 HANA Private Cl

  • Wanbury embarks on digital transformation with SAP S/4HANA private cloud implementation

    23 Apr 2025, 10:54AM Wanbury Ltd has announced a strategic move to adopt the SAP S/4HANA Private Cloud platform as part of its broader digital transformation initiative. I

  • Wanbury - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    23 Apr 2025, 10:28AM Intimation to implement SAP S/4 HANA Private Cloud Platform

  • Wanbury - Disclosure under SEBI Takeover Regulations

    19 Apr 2025, 11:24PM Expert Chemicals (India) Pvt. Ltd. has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of I

  • Wanbury has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2025

    18 Apr 2025, 8:31PM As of March 2025, 39.76% is owned by Promoters and 60.24% by Public. <p align=justify> Among Promoters holding, Indian Promoters holds 30.53% and Fore

  • Wanbury - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    11 Apr 2025, 5:47PM Certificate pursuant to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations,2018 of Wanbury Limited

  • Wanbury - Certificate under SEBI (Depositories and Participants) Regulations, 2018

    11 Apr 2025, 5:43PM Wanbury Limited has informed the Exchange about Certificate under Reg 74(5) of SEBI (Depositories and Participants) Regulations, 2018

  • Wanbury - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A

    7 Apr 2025, 3:47PM <b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border='1px'><tr> <td><b>Sr. No.</b></td

  • Wanbury - Press Release

    3 Apr 2025, 9:43AM Wanbury Limited has informed the Exchange regarding a press release dated April 03, 2025, titled ""Intimation of improved capacity utilization for Q4

  • Wanbury - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    3 Apr 2025, 9:48AM Intimation of Improved capacity utilization for Q4 and improved margins

  • Wanbury - Press Release

    2 Apr 2025, 5:05PM Wanbury Limited has informed the Exchange regarding a press release dated April 02, 2025, titled ""Intimation of schedule of Investors/ Analysts Plant

  • Wanbury - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    2 Apr 2025, 5:09PM Intimation of schedule of Investors/ Analysts Plant Visit

  • Wanbury - Trading Window-XBRL

    27 Mar 2025, 3:08PM WANBURY LIMITED has informed the Exchange about Closure of Trading Window

  • Wanbury - Trading Window

    27 Mar 2025, 3:05PM Wanbury Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015

  • Wanbury - Press Release

    24 Mar 2025, 12:31PM Wanbury Limited has informed the Exchange regarding a press release dated March 24, 2025, titled ""Press Release - Wanbury Limited"".

  • Wanbury Limited launches two new products: C-RED Iron Tablets and Ketamine Hydrochloride API

    24 Mar 2025, 1:00PM Mumbai, India &ndash; Wanbury Limited, a leading pharmaceutical company with a significant presence in the global API market and domestic branded form

  • Wanbury - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    24 Mar 2025, 12:39PM Wanbury Limited (\Wanbury\), a pharmaceutical company with a presence in the global API market and domestic branded formulations, please to inform tha

  • Wanbury - Press Release

    6 Mar 2025, 8:47AM Wanbury Limited has informed the Exchange regarding a press release dated March 06, 2025, titled ""Disclosure under Regulation 30 of SEBI (Listing Obl

  • Wanbury Ltd achieves significant interest cost savings through debt refinancing

    6 Mar 2025, 9:32AM Wanbury Limited ("Wanbury"), a pharmaceutical company with a strong presence in the global API market and domestic branded formulations, has reached a

  • Wanbury - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    6 Mar 2025, 8:52AM Disclosure under regulation 30 of SEBI (LODR) Regulations, 2015 Press Release on Refinancing of Outstanding Debentures

  • Wanbury - Announcement under Regulation 30 (LODR)-Allotment

    28 Feb 2025, 5:29PM This is to inform that the Day to Day Affairs Committee (Constituted by the Board of Directors of Wanbury Limited) in its meeting held today have appr

  • Wanbury - Allotment of Securities

    28 Feb 2025, 5:27PM Wanbury Limited has informed the Exchange regarding allotment of 1750 securities pursuant to Preferential Issue at its meeting held on February 28, 20

  • Wanbury - Shareholder Meeting / Postal Ballot-Scrutinizer\s Report

    20 Feb 2025, 7:41PM Submission of Voting Results of the EOGM

  • Wanbury - Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent

    20 Feb 2025, 7:28PM WANBURY LIMITED has informed the Exchange about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent

  • Wanbury - Shareholders meeting

    20 Feb 2025, 7:17PM Wanbury Limited has submitted the Exchange a copy Srutinizers report of Extraordinary General Meeting held on February 20, 2025

  • Wanbury - General Updates

    20 Feb 2025, 7:05PM Intimation under Regulation 30 and Schedule III of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 on appointment of Mr. Ma

  • Wanbury - Intimation Under Regulation 30 And Schedule III Of The SEBI (Listing Obligations & Disclosure Requirements) Regulat

    20 Feb 2025, 7:02PM Appointment of Non-Executive Independent Directors.

  • Wanbury - Announcement under Regulation 30 (LODR)-Change in Directorate

    20 Feb 2025, 6:58PM Appointment of Non-Executive Independent Directors in the Company.

  • Wanbury - Change in Director(s)

    20 Feb 2025, 6:56PM Wanbury Limited has informed the Exchange regarding Change in Director(s) of the company.

  • Wanbury - Announcement under Regulation 30 (LODR)-Change in Management

    20 Feb 2025, 6:46PM Intimation under Regulation 30 on appointment of Mr. Manojkumar Khubchand Gursahani and Mr. Pallavur Sankar Dass Vaidyanathan as the Non-Executive Ind

  • Wanbury - Appointment

    20 Feb 2025, 6:21PM Wanbury Limited has informed the Exchange regarding Appointment of Mr Manojkumar Khubchand Gursahani as Non- Executive Independent Director of the com

  • Wanbury - Shareholders meeting

    20 Feb 2025, 1:59PM Wanbury Limited has informed the Exchange about Shareholders meeting

  • Wanbury - Shareholder Meeting / Postal Ballot-Outcome of EGM

    20 Feb 2025, 2:02PM Summary of Proceedings of EOGM February 20, 2025

  • Wanbury - Press Release

    18 Feb 2025, 4:25PM Wanbury Limited has informed the Exchange regarding a press release dated February 18, 2025, titled ""Press release on Q3 & 9M FY25 Financial Results"

  • Wanbury - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    18 Feb 2025, 4:30PM Press Release on Q3 and 9M FY25 Financial Results.

  • Wanbury - Integrated Filing- Financial

    13 Feb 2025, 12:09AM Integrated Filing (Financials) Revised

  • Wanbury - General Updates

    13 Feb 2025, 12:07AM Unaudited Financials results for the quarter and nine months ended 31st December, 2024.

  • Wanbury - Integrated Filing (Financial)

    13 Feb 2025, 12:14AM Revised Integrated Filing (Financial)

  • Wanbury - Announcement under Regulation 30 (LODR)-Issue of Securities

    12 Feb 2025, 11:59PM Grant of 200000 ESOP's to employees of the Company.

  • Wanbury - Announcement under Regulation 30 (LODR)-Raising of Funds

    12 Feb 2025, 11:56PM Issue of Senior, Secured, Unrated, Unlisted, Redeemable and Non-Convertible Debentures upto Rs: 200 Crores. At present the funds being raised are of R

  • Wanbury - ESOP/ESOS/ESPS

    12 Feb 2025, 11:51PM Wanbury Limited has informed the Exchange regarding Grant of 200000 Options.

  • Wanbury - Others

    12 Feb 2025, 11:48PM Wanbury Limited has informed the Exchange about Others

  • Wanbury - Outcome of Board Meeting

    12 Feb 2025, 11:33PM Revised Outcome of BM for the quarter ended and nine months ended 31st December, 2024

  • Wanbury - Integrated Filing (Financial)

    12 Feb 2025, 8:59PM Integrated Filing (Financials) for the quarter and nine months ended 31st December, 2024.

  • Wanbury Q3 net profit down 88.12% at Rs 1.22 cr

    12 Feb 2025, 8:50PM The company reported standalone net profit of Rs 1.22 crore for the quarter ended December 31, 2024 as compared to Rs 10.27 crore in the same period l

  • Wanbury - Integrated Filing- Financial

    12 Feb 2025, 8:50PM Integrated Filing (Financials) for the quarter and nine months ended 31st December, 2024

  • Wanbury - Unaudited Financial Results For The Quarter And Nine Months Ended 31St December, 2024.

    12 Feb 2025, 8:46PM Unaudited Financial results for the quarter and nine months ended 31st December, 2024.

  • Wanbury - Financial Result Updates

    12 Feb 2025, 8:36PM Wanbury Limited has submitted to the Exchange, the financial results for the period ended December 31, 2024.

  • Wanbury - Board Meeting Outcome for Outcome Of Board Meeting Held On 121H February, 2025 In Terms Of Regulation 30 Of SEBI (L

    12 Feb 2025, 8:28PM Outcome of Board Meeting held on 121h February, 2025 in terms of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations,

  • Wanbury - Outcome of Board Meeting

    12 Feb 2025, 8:18PM Outcome of Board Meeting held on 121h February, 2025 in terms of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations,

  • Wanbury - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    29 Jan 2025, 6:29PM Wanbury Limited Appointed Mr. Rashesh Patel as Corporate Director - India Formulation Business.

  • Wanbury - Press Release

    29 Jan 2025, 6:23PM Wanbury Limited has informed the Exchange regarding a press release dated January 29, 2025, titled ""Wanbury Limited Appointed Mr. Rashesh Patel as Co
Load More
Show Less

Key fundamentals

Evaluate the intrinsic value of Wanbury Ltd stock 

Name March-24 March-23 March-22 March-21 March-20
Assets 137.8934 56.8788 69.2111 -42.2402 6.6335
Liabilities 137.8934 56.8788 69.2111 -42.2402 6.6335
Equity 32.7455 32.7055 32.6655 25.0151 24.9951
Gross Profit 70.0022 23.1719 35.3128 18.0192 23.4452
Net Profit 30.3995 -10.3958 81.4739 -12.6057 64.4622
Cash From Operating Activities 4.017 19.7972 40.5231 16.6815 44.127
NPM(%) 5.28 -2.08 15.93 -3.21 17.54
Revenue 575.6498 499.6469 511.1857 392.5175 367.4547
Expenses 505.6476 476.475 475.8729 374.4983 344.0095
ROE(%) 78.43 -26.82 210.22 -32.52 166.32

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day
29 Jul 2010 1 10 0 78.6
12 Mar 2009 0.5 5 0 45.5
13 Sep 2007 2 20 0 115

Peers

Other companies within the same industry or sector that are comparable to Wanbury Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 840.85 0.23 11.87 143.56 1321.50 1.37
Lotus Eye Hospital and Institute Ltd 81.36 2.94 339.00 523.13 14.01 0.61
Vaishali Pharma Ltd 13.72 -0.15 457.33 269.64 2.76 0.00
Astec Lifesciences Ltd 693.05 -1.61 0.00 493.27 -687.11 0.00

Company Info

The Company was incorporated on 11th August 1988, as a Private Limited Company under the name of `Pearl Distributors Private Limited'. The name of the Company was changed to "Pearl Organics Private Limited" on 17th January, 1991. The Company was converted into a Public Limited Company on 6th August, 1991. The main object of the Company is to undertake the manufacture and sale of pharmaceuticals, medicines, drugs and organic chemicals. A substantial portion of the production of these products are intended for exports. The Company has set up a full-fledged export marketing division consisting of experienced professionals. The Company has already secured orders worth Rs 1.07 crores from West European Countries. The Company is in the process of negotiating further orders with foreign buyers for export of its products. The main objects of the Company are fully set out in Memorandum of Association of the Company. The Company has no subsidiary. The Company has been principally promoted by Mr.K. Chandran along with his associates Mr K Chandran has a rich experience of over 12 years in marketing of pharmaceutical formulation in local & international markets. During his 12 years tenure he has worked in various capacities including as business manager in one of the largest pharmaceutical company. He was also head of export division of an export oriented pharmaceutial Company. 2004 - Pearl Organics to establish new R&D centre in Mumbai 2006 - Wanbury acquires generic company in Spain 2007 - Wanbury Ltd has recommended dividend of Rs 2 per equity share i.e. @ 20% 2008 - Wanbury Ltd has recommended dividend of Rs 0.50 per equity shares i.e. @5% 2010 - Wanbury Ltd has recommended a dividend of Rs. 1/- per equity share 2016 - Wanbury Won Pharma IT Innovation Award 2016 - Wanbury bags 2 awards at recently held AWACS awards 2024 -Wanbury Limited received a Certificate of Suitability (CEP) forthe launch of its new product, Dextromethorphan (API). -Wanbury Limited wins two Safety Awards for its API Manufacturing site in Patalganga for the third consecutive year at the Maharashtra Safety Awards Competition 2023, conducted by Maharashtra State Government.

The Company was incorporated on 11th August 1988, as a Private Limited Company under the name of `Pearl Distributors Private Limited'. The name of the Company was changed to "Pearl Organics Private Limited" on 17th January, 1991. The Company was converted into a Public Limited Company on 6th August, 1991. The main object of the Company is to undertake the manufacture and sale of pharmaceuticals, medicines, drugs and organic chemicals. A substantial portion of the production of these products are intended for exports. The Company has set up a full-fledged export marketing division consisting of experienced professionals. The Company has already secured orders worth Rs 1.07 crores from West European Countries. The Company is in the process of negotiating further orders with foreign buyers for export of its products. The main objects of the Company are fully set out in Memorandum of Association of the Company. The Company has no subsidiary. The Company has been principally promoted by Mr.K. Chandran along with his associates Mr K Chandran has a rich experience of over 12 years in marketing of pharmaceutical formulation in local & international markets. During his 12 years tenure he has worked in various capacities including as business manager in one of the largest pharmaceutical company. He was also head of export division of an export oriented pharmaceutial Company. 2004 - Pearl Organics to establish new R&D centre in Mumbai 2006 - Wanbury acquires generic company in Spain 2007 - Wanbury Ltd has recommended dividend of Rs 2 per equity share i.e. @ 20% 2008 - Wanbury Ltd has recommended dividend of Rs 0.50 per equity shares i.e. @5% 2010 - Wanbury Ltd has recommended a dividend of Rs. 1/- per equity share 2016 - Wanbury Won Pharma IT Innovation Award 2016 - Wanbury bags 2 awards at recently held AWACS awards 2024 -Wanbury Limited received a Certificate of Suitability (CEP) forthe launch of its new product, Dextromethorphan (API). -Wanbury Limited wins two Safety Awards for its API Manufacturing site in Patalganga for the third consecutive year at the Maharashtra Safety Awards Competition 2023, conducted by Maharashtra State Government.

Read More

Parent Organisation

Wanbury Ltd.

Founded

11/08/1988

Managing Director

NSE Symbol

WANBURYEQ

FAQ

The current price of Wanbury Ltd is ₹ 244.42.

The 52-week high for Wanbury Ltd is ₹ 258.25 and the 52-week low is ₹ 240.30.

The market capitalization of Wanbury Ltd is currently ₹ 800.98. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Wanbury Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Wanbury Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Wanbury Ltd shares.

The CEO of Wanbury Ltd is , who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT